From a translational point of view, our observations also suggest that the efficacy of FGF19/FGFR4 targeted therapies that are currently being devised for HCC treatment [56], [66], [69] could be enhanced by simultaneously interfering with the AR/EGFR system. The gene discussed is FGF19; the disease is hepatocellular carcinoma.